Aditi Dutt

Array ( [id] => 19081899 [patent_doc_number] => 20240108700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s) [patent_app_type] => utility [patent_app_number] => 18/540403 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281582 [patent_doc_number] => 20240218056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => NUCLEOCAPSID-SPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION THEREWITH [patent_app_type] => utility [patent_app_number] => 18/530063 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18530063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187853 [patent_doc_number] => 20240166766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/525736 [patent_app_country] => US [patent_app_date] => 2023-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18525736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065709 [patent_doc_number] => 20240100135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Methods of Treating an Optic Disease in a Subject [patent_app_type] => utility [patent_app_number] => 18/521777 [patent_app_country] => US [patent_app_date] => 2023-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18521777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051178 [patent_doc_number] => 20240093147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME [patent_app_type] => utility [patent_app_number] => 18/505387 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19709290 [patent_doc_number] => 20250019432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => CELL-BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/384623 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18384623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187824 [patent_doc_number] => 20240166737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => MSLN AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/493367 [patent_app_country] => US [patent_app_date] => 2023-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18493367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816029 [patent_doc_number] => 20230390368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s) [patent_app_type] => utility [patent_app_number] => 18/455179 [patent_app_country] => US [patent_app_date] => 2023-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18455179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187829 [patent_doc_number] => 20240166742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => MOLECULES THAT BIND TO AND STABILIZE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2) [patent_app_type] => utility [patent_app_number] => 18/363237 [patent_app_country] => US [patent_app_date] => 2023-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18363237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877537 [patent_doc_number] => 20240000906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) [patent_app_type] => utility [patent_app_number] => 18/359633 [patent_app_country] => US [patent_app_date] => 2023-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18359633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626747 [patent_doc_number] => 20230285553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => MATERIALS AND METHODS FOR MITIGATING IMMUNE-SENSITIZATION [patent_app_type] => utility [patent_app_number] => 18/309011 [patent_app_country] => US [patent_app_date] => 2023-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971971 [patent_doc_number] => 20240052063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => Binding Proteins 2 [patent_app_type] => utility [patent_app_number] => 18/069124 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612415 [patent_doc_number] => 20230279147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => H1.0K180ME2 ANTIBODIES, METHODS OF MAKING AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/054427 [patent_app_country] => US [patent_app_date] => 2022-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628252 [patent_doc_number] => 20230287106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE [patent_app_type] => utility [patent_app_number] => 18/053842 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376243 [patent_doc_number] => 20230151326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => Simplified Compositions and Methods for Generating Neural Stem Cells from Human Pluripotent Stem Cells [patent_app_type] => utility [patent_app_number] => 17/973020 [patent_app_country] => US [patent_app_date] => 2022-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17973020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691301 [patent_doc_number] => 20250009846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => RECOMBINANT PROTEIN OF NERVE GROWTH FACTOR MUTANT AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/686041 [patent_app_country] => US [patent_app_date] => 2022-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18686041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981065 [patent_doc_number] => 20220347101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => ENZYME DELIVERY SYSTEMS AND METHODS OF PREPARATION AND USE [patent_app_type] => utility [patent_app_number] => 17/864285 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990200 [patent_doc_number] => 20220356237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/853108 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981285 [patent_doc_number] => 20220347321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => EXPRESSION OF NEUROPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/809376 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389910 [patent_doc_number] => 20230158128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC AND NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/850383 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850383 [rel_patent_id] =>[rel_patent_doc_number] =>)